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Viral reverse transcriptaserful tools for the introduction of transgenes into mammalian cells and for long-
term gene expression. However, their application is often limited by a rapid loss of bioactivity: retroviruses
spontaneously loose activity at 37 °C, with a half-life of 4 to 9 h depending on the retrovirus type. We sought
to determine which components of the retrovirus are responsible for this loss in bioactivity and to obtain a
quantitative characterization of their stability. To this end, we focused on RNA and viral proteins, two major
components that we hypothesized may undergo degradation and negatively inﬂuence viral infectivity.
Reverse transcription PCR (RT-PCR) targeting RNA encoding portions of the viral genome clearly
demonstrated time-dependent degradation of RNA which correlated with the loss in viral bioactivity.
Circular dichroism spectroscopy, SDS-PAGE and two-dimensional SDS-PAGE analyses of viral proteins did not
show any change in secondary structure or evidence of proteolysis. The mechanism underlying the
degradation of viral RNA was investigated by site-directed mutagenesis of proteins encoded by the viral
genome. Reverse transcriptase and protease mutants exhibited enhanced RNA stability in comparison to wild
type recombinant virus, suggesting that the degradation of RNA, and the corresponding virus loss of activity,
is mediated by the reverse transcriptase enzyme.
© 2008 Elsevier Inc. All rights reserved.Introduction
Retroviral vectors have been widely used in gene therapy
applications (Gordon and Anderson, 1994; Pages and Bru, 2004),
including the ﬁrst successful gene therapy protocol for X-linked
severe combined immunodeﬁciency (SCID-X1) (Aiuti et al., 2002;
Cavazzana-Calvo et al., 2000). Retroviruses have several advantages
over other vectors, including the ability to permanently modify the
nuclear genome of the host, the relative simplicity of the retroviral
genome and ease of use (Barquinero, Eixarch, and Perez-Melgosa,
2004; Kohn et al., 2003; Mitani, Wakamiya, and Caskey, 1993; Relph,
Harrington, and Pandha, 2004; Robbins and Ghivizzani, 1998). Since
the ﬁrst gene therapy clinical trials in the early 1990's, Moloney
murine leukemia virus (MMuLV)-based vectors have been the
preferred tool for stable genetic modiﬁcation. A total of 254 clinical
trials have relied on this type of vector, accounting for 28% of the
total number of viral gene therapy clinical trials approved world-
wide (Barquinero, Eixarch, and Perez-Melgosa, 2004; Kohn et al.,
2003; Relph, Harrington, and Pandha, 2004).7, Boston, MA 02114, USA. Fax:
ali), ireis@sbi.org
l rights reserved.Among the requirements for successful gene therapy, highly
efﬁcient delivery of genetic material and stability of the gene carrier
are indispensable. One problem limiting successful clinical application
of MMuLV-based vectors is inefﬁcient gene transfer. This inefﬁciency is
attributable to several factors: (a) murine gamma-retroviruses infect
only actively dividing cells (Miller, Adam, and Miller, 1990; Roe et al.,
1993), (b) murine gamma-retroviruses are rapidly inactivated by the
human complement system (Chuck, Clarke, and Palsson,1996; Takeuchi
et al., 1996) and (c) virions have a short half-life of 4–9 h, limiting viral
stability and titer (Chuck, Clarke, and Palsson,1996; Le Doux et al.,1999;
Merten et al., 2001). Most research on murine gamma-retrovirus-
mediated gene transfer has focused on the development of vector
constructs and packaging cell lines and optimization of the delivery
process (Daly and Chernajovsky, 2000; Davis, Morgan, and Yarmush,
2002; Davis et al., 2004; Hanenberg et al., 1996; Le Doux et al., 1999).
Efforts have been made to address retroviral vector shortcomings by
improving viral titers via concentration processes (Paul et al., 1993;
Pham et al., 2001; Reeves and Cornetta, 2000), producing retrovirus at a
low temperature to decelerate the rate of decay (Kotani et al., 1994;
Kwon and Peng, 2005), engineering packaging cells to produce
retroviruses resistant to inactivation by human serum (Cosset et al.,
1995; Mason et al., 1999; Pensiero et al., 1996) and removing
transduction inhibitors secreted by the packaging cell lines (Le Doux
et al., 1996; Le Doux, Morgan, and Yarmush, 1998 Le Doux";,1999).
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signiﬁcant limitations imposed by viral instability at physiological
temperature (Kotani et al., 1994; Le Doux et al., 1999) the mecha-
nism by which decay occurs is still unclear. The three components
that can undergo degradation are the membrane enveloping the
virus, the protein component and the nucleic acid. Previous studies
showed that viral envelop lipid composition and lipid oxidation
affect viral stability (Poryvaev, 1995, 1996; Poryvaev and Zykova,
1995) and in a recent study Beer et al. (2003) showed that high
cholesterol levels in the viral lipid shell decrease thermal viral
stability.
Herewe investigate the stability of the viral RNA and capsid proteins
using biophysical and molecular techniques. Based on our observations,
we propose a mechanism for the decay of MMuLV-derived vectors
involving the viral reverse transcriptase.
Results
Viral RNA decays on a time scale similar to that of the loss in bioactivity
In order to examine possible relationships between retroviral
decay and decay of viral components, we began by examining the
stability of the viral RNA. Solutions of MMuLV-based vector were
incubated at 37 °C and 4 °C and samples were collected at different
time points and stored at −80 °C. RNA was isolated and analyzed byFig.1. End point RT-PCR analysis (A), and Northern blot (B) of retroviral RNA decay. Virus
was incubated at 37 °C and 4 °C. RT-PCR was performed on samples collected at 0 and
24 h, and products were analyzed on agarose gel and stained with SYBR Green.
Representative data from 3 decay experiments are shown. Northern blot analysis was
performed on virus samples incubated at 37 °C and collected at 0 and 24 h. End point
RT-PCR for the endogenous reverse transcription (C).Virus was incubated at 37 °C and
4 °C. RT-PCR was performed on samples collected at 0 and 24 h and products were
analyzed on agarose gel and stained with SYBR Green. Representative data from 3
experiments are shown. The arrow in (B) indicates the size of the intact RNA genome.
Fig. 2. Quantitative analysis of RNA decay and viral bioactivity. Virus was incubated at
(A) 37 °C and (C) 4 °C; samples were collected at different intervals of time for analysis
by real time RT-PCR and transduction assays. RNA integrity and viral bioactivity (data
obtained from panel (A)) were linearly correlated (r2=0.99). Data points in A and C are
mean±standard deviation, n=3. Data points in B are mean activity values and RNA
integrity values for each time point from 3 experiments.end point RT-PCR with primers directed at the LacZ region. End point
data clearly showed a decrease in the intensity of ampliﬁed RNA as a
function of time for the virus incubated at 37 °C, but not for the
samples incubated at 4 °C (Fig. 1A). Northern blot analysis (Fig. 1B)
conﬁrmed the degradation of RNA at 37 °C. After 24 h incubation, no
highmolecular weight RNAwas visible and the overall signal intensity
of the viral RNA decreased as well. The possibility that Natural
Endogenous Reverse Transcription (NERT) is responsible for viral RNA
degradationwas investigated at 37 °C and 4 °C at different time points
(Fig. 1C). No signiﬁcant increase of NERT products were found after
24 h incubation at neither temperatures.
Analysis of viral RNA integrity by real time PCR demonstrated
exponential decay at 37 °C (Fig. 2A). The rate of RNA decay was similar
to the rate of loss in viral bioactivity as measured by LacZ transduction
assays (Fig. 2A), with a linear correlation (r2=0.99) between the two
(Fig. 2B). When the virus was incubated at 4 °C, no measurable RNA
decay occurred, while a slight (20%) loss in viral bioactivity over 24 h
was observed (Fig. 2C). Similar results were obtained using primers
speciﬁc for the viral gag region (data not shown).
Fig. 3. RNA decay in protease (A), and reverse transcriptase mutants (B–D). Virus samples were incubated at 37 °C, and samples were collected at different time intervals of time and
analyzed by real time RT-PCR. All mutants exhibit enhanced RNA stability compared to the wild type virus (in gray). Data points represent mean±standard deviation, n=3.
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RNA stability
Protease and reverse transcriptase mutants were obtained by
site-directed mutagenesis on pVPack-GP plasmid. Wild type virus
was obtained from transient transfection under the same conditions
as the mutants, and the wild type virus produced under both stable
and transient conditions showed the same bioactivity and decay
kinetic. Despite that retroviral proteases share limited amino acid
homology with members of the aspartyl protease family, the active
site residues Asp-Thr-Gly are highly conserved. Substitution of the
aspartic acid residue at position 27 of MMuLV protease with
asparagine (D27N) abrogates protease activity, inhibiting viral
maturation and infectivity, while maintaining the ability to form
immature (uncondensed) virus particles (Fu et al., 2006; Fu and Rein,
1993; Kohl et al., 1988).
Reverse transcriptase mutants were previously described by Blain
and Goff (1993); in these mutants DNA–RNA (RNase H) and RNA–RNA
(RNase H⁎) nuclease activities of the viral reverse transcriptase were
functionally separated. Based on the cited work we produced three
viral mutants: mutation R657S which selectively reduced RNase H⁎
but not RNase H activity; mutation Y586F which abolished RNase H
activity, but not RNase H⁎ activity; and mutation D524N which
reduced both RNase H and RNase H⁎ activities, as compared to the
wild type enzyme. RNA degradation in the mutant viruses was
investigated over a period of 24 h by end point and real time RT-PCR
and compared to the wild type virus. All mutants exhibited a slower
rate of RNA degradation than wild type. The protease mutant
displayed linear RNA degradation kinetics, with approximately 50%
RNA degradation after 18 h, instead of the 6 h observed for the wild
type virus, and 30 to 40% RNA integrity remaining at 24 h (Fig. 3A).
Mutant R657S retained 80% of its RNA integrity after 24 h (Fig. 3B),
while Y585F and D524N retained 60% and 70% of their initial RNA
integrity at 24 h, respectively (Figs. 3C, D). We have not yet been ableto correlate the RNA degradation results to viral bioactivity data for
mutant nucleases. This could be because themutants are not infective,
or their titer is not sufﬁcient.
Retroviral proteins are stable over a 13 h period at 37 °C
To investigate the stability of retroviral proteins, we employed two
techniques: far and near UV CD spectroscopy measurements were
performed to detect large changes in the secondary structure of the
viral proteins, while SDS-PAGE and 2D-PAGE were utilized to monitor
non speciﬁc degradation or speciﬁc cleavage of the proteins. The
quality of the samples for CD analysis was conﬁrmed by SDS-PAGE and
contaminating bands were negligible. CD spectra contained a negative
peak at approximately 217 nm, indicating beta-sheet structure, and a
peak at 290 nm, corresponding to aromatic amino acids. Retrovirus
was incubated at 37 °C for 13 h, and CD spectra were collected every
hour. No major change in intensity or positionwas observed for either
peaks over a 13 h period at 37 °C (Fig. 4A). Degradation of viral
proteins was investigated by SDS-PAGE (Fig. 4B) and 2D-PAGE (data
not shown). No changes in protein patterns were detected for
retrovirus incubated at 37 °C for up to 24 h, indicating that viral
proteins did not degrade over this time period.
Discussion
The decay of retroviral activity is a signiﬁcant factor contributing to
the inefﬁciency of retroviruses as vectors for gene transfer. Since these
vectors are non-replicating, only two functions of the retroviral life
cycle are critical for the success of a therapeutic protocol: ﬁrst, the
viral interactionwith the host cell surface and introduction of the viral
genome into the cell; and second, the integration of the viral genome
into the cellular genome and expression of viral proteins by the host
cell. Throughout both of these steps the integrity of the viral envelope,
viral proteins and genomic material is essential: degradation of one or
Fig. 4. (A) CD spectra of viral particles incubated at 37 °C over 13 h. No changes in the shape and intensity of the spectra are observed. Detail of (a) aromatic region, and (b) beta-sheet
region conﬁrm no changes in the spectra. (B) SDS-PAGE analysis of viral protein at 0 h and after 24 h of incubation at 37 °C. In the two sample sets different amounts were loaded to
show high and low abundance proteins. Onlymajor viral proteins as envelope (ENV), capsid (CA) andmatrix (MA) are visible and no degradation is detectable. Other viral proteins are
not visible because these are too small or poorly represented.
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bioactivity. Studies reporting the effect of envelope lipid composition
and oxidation on virus stability have been previously published, but
no investigation on viral genome and protein stability has yet been
reported. To better understand the mechanism underlying retroviral
decay we investigated the stability of the retroviral RNA and proteins.
We ﬁrst investigated the stability of viral RNA by end point and real
time RT-PCR and northern blot. Despite that PCR analysis only targets
a small region of the genome, degradation of this segment reﬂects the
loss of total genomic RNA; we consider the amount of RNA template
present at time 0 h to be 100%, while the residual template amount at
24 h is expressed as a percentage of the initial amount. This
assumption is essential to understand the apparent discrepancy
observed between PCR and transduction assays. Our data show a
decrease in RNA template over 24 h when the virus was incubated at
37 °C but not at 4 °C (Fig. 1A). The same kinetic proﬁle (Fig. 1B) and the
linear correlation (Fig. 2B) found between viral activity, as measured
by transduction assays, and RNA template amount, measured by real
time PCR experiments, strongly suggests that RNA degradation
contributes to decay. Northern blot data (Fig. 1B) clearly show
degradation of viral RNA (corresponding to an intact genome of
3.5 kb). After 24 h incubation of the virus particles at 37 °C high
molecular weight RNAmolecules are not detected, and the decrease of
the signal intensity suggests that a complete degradation of RNA hasalso occurred. At 0 h, despite that full length genomic RNA of 3.5 kb is
detectable (Fig. 1B, black arrow), partial RNA degradation is visible;
this degradation can be accounted for by the RNA puriﬁcation process
and by the fact that the 0 h sample derives from multiple virus
harvests and it is a mixture of viral particles that spent up to 16 h at
37 °C. We also investigated a possible role for NERT in RNA
degradation using PCR analysis. The data shows no signiﬁcant amount
of DNA is produced by NERT after 24 h incubation (Fig. 1C) at both
temperatures.
Inside of viral particles, RNA degradation can be the result of
endogenous or exogenous RNase activity (Garret and Grisham, 1995),
or some combination thereof. Endogenous RNase activity can be
attributed to the viral reverse transcriptase (RT), while exogenous
activity may be ascribed to cellular RNase encapsulated in the virus
during budding. Reverse transcriptase retro transcribes RNA to form a
RNA–DNA hybrid using two separate enzymatic activities: a DNA
polymerase activity, which is capable of using either RNA or DNA as a
template; and a ribonuclease H activity, which degrades the viral
genomic RNA in the newly synthesized RNA–DNA hybrid (Goff, 1990;
Jacobo-Molina and Arnold, 1991). RNase H was thought to degrade
RNA only when present in a RNA–DNA hybrid (RNase H activity);
however, it was shown that MMuLV RT is capable of degrading RNA
found in a RNA–RNA duplex form (RNase H⁎ activity) (Ben-Artzi et al.,
1992).
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created D27N, a MMuLV protease mutant (PR¯) whose proteolytic
activity is suppressed. Virus containing the PR¯ mutant does not
mature and active viral RT is not produced by proteolytic processing of
Gag-Pol (Kohl et al., 1988; Traktman and Baltimore, 1982; Witte and
Baltimore,1978). Thismutantmaintained 40% RNA integrity after 24 h,
with degradation kinetics that were qualitatively different from wild
type (Fig. 3A). While the wild type viral RNA decayed exponentially,
the PR¯ mutant appeared to decay at a constant rate. The fact that 1)
there exists a lack of enzymatic activity in the PR¯ mutant, 2) that the
viral genome exists in a different conformation (D'Souza and
Summers, 2004; Hibbert and Rein, 2005; Murti, Bondurant, and
Tereba, 1981), and 3) that the decay rate is constant, all suggest that
the mechanism for RNA degradation in the PR¯ mutant is different
from that of wild type. On the basis of these observations, we can
hypothesize two different scenarios for RNA degradation: 1) that the
reverse transcriptase in the non-mature virus has little or no activity
and that exogenous RNases are responsible for RNA degradation; or 2)
that the lower amount of secondary structure in the RNA of non-
mature virus prevents the viral RNA from becoming a target of RNase
H⁎ activity within the viral RT; also in this case, exogenous RNase may
be responsible for the viral RNA degradation seen in this mutants.
Important is the fact that non-mature viral particles are more
permeable to exogenous molecules compared to mature particles,
therefore exogenous RNase can have access to the genomic RNA.
Our observations are in agreement with recent ﬁndings by Vu et al.
(2007): in this study MMuLV mutant with an extended half-life (24 h
instead of 5–6 h) was created by directed evolution. The mutation
responsible for the enhanced half-life was mapped to the viral
protease where a glycine was substituted with a glutamic acid. The
researchers did not investigate the mechanism underlying the
increased half-life, but, in line with our hypothesis, the mutation
may havemodiﬁed the substrate speciﬁcity or proteolytic efﬁciency of
the viral protease. In either case, it is possible that viral maturation
was slower compared to wild type thus yielding a more stable virus.
Mutants of the viral RT with altered substrate speciﬁcities were
created and characterized by Blain and Goff (1993). Through
mutational studies, the researchers functionally separated the
DNA–RNA and the RNA–RNA RNase activities of the enzyme,
yielding reverse transcriptase mutants with variable levels of each
of these activities. To investigate a possible role for the RNase H and
RNase H⁎ activities in RNA decay, we produced three virus mutants:
R657S, Y586F, and D524N. Mutant R657S has RNase H activity
comparable to the wild type, but less than 1% of the wild type
RNase H⁎ activity; mutant Y586F has 5% of the wild type RNase H
activity and 100% RNase H⁎ activity; and mutant D524N has 10–25%
of the wild type RNase H activity and less than 1% of RNase H⁎
activity.
The rate of RNA decay in each mutant was quantiﬁed by real
time RT-PCR after incubation at 37 °C up to 24 h (Fig. 3). All mutants
exhibited a decreased rate of RNA degradation, with the R657S and
D524N mutants each retaining approximately 80% RNA integrity at
24 h, while mutant Y586F retained 60% RNA integrity. These results
clearly demonstrate that abrogation of RNase H⁎ (R657S, D524N)
activity enhances the stability of the viral genome. The higher RNA
stability found in Y586F mutant can be the result of a lower ability
of this enzyme to bind the substrate. A crystal structure of a wild
type enzyme complexed with a DNA–RNA hybrid showed that Y586
binds the phosphate group of the DNA strand in the DNA–RNA
hybrid (Lim et al., 2006). Likely, a similar interaction is established
with the phosphate group in the RNA–RNA pairing. These data
suggest also that the two enzymatic activities RNase H and RNase
H⁎ are tightly connected, as it should be expected, and mutations in
one affect the other.
Our data suggest that the RNase activity of the viral RT plays a
role in viral RNA degradation. In the immature virion, the two copiesof the RNA genome form a fragile dimer that becomes more stable
during maturation because of an increment of kissing loops and in
the secondary structure (Fu et al., 2006; Riggin, Bondurant, and
Mitchell, 1975). However, this increment in the secondary structure
may also make the RNA more vulnerable to the RNase H⁎ activity
from the viral RT.
We ruled out that degradation of viral proteins is responsible for
the observed drop in viral infectivity. To probe protein stability
during viral decay we examined the stability of the virus protein
components by CD spectroscopy and SDS-PAGE. CD spectroscopy
quantiﬁes the secondary structure of proteins and small changes in
secondary structure content can be detected (Cantor and Schimmel,
1980). CD spectroscopy has previously been used to study the
temperature-induced decay of the Respiratory Syncytial Virus
(Ausar et al., 2007; Ausar et al., 2005). CD spectra of puriﬁed
virus particles showed no changes during incubation at 37 °C for a
period of 13 h (Fig. 4A). This lack of variation in the CD spectrum
suggests that no signiﬁcant changes occurred in protein secondary
structure under these conditions. It should be noted that although
RNA also has a characteristic CD spectrum, which could partially
overlap with the protein spectrum, RNA in the virus is present at
much lower quantities than protein and no interference can be
expected. The CD spectra obtained are the sum of the contribution
of each individual viral protein, but different proteins contribute
differently to the spectra depending on their abundance. The most
represented proteins are the glycoprotein gp70 and the capsid
protein p30 and they should be considered the major player in CD
spectra variation, or lack of it, as it is in this case. SDS-PAGE (Fig.
4B) and two-dimensional SDS-PAGE analyses (data not shown)
conﬁrmed that protein degradation does not occur after 24 h at
37 °C, as no change was observed in the gel pattern. Our
observations do not include proteins as trans-membrane (TM),
nucleocapsid (NC) proteins, the polymerase and the integrase,
because of the small molecular weight and/or their low abundance.
Our work demonstrates that MMuLV-derived vector activity
decay is correlated with viral RNA degradation and virus particle
maturation. We demonstrated that viral RNA degradation is
mediated by the viral reverse transcriptase through its RNase H⁎
activity, and mutations at the RNaseH catalytic site affects RNA
stability kinetic.
Our ﬁndings suggest that it may be possible to produce a more
stable MMuLV-derived retroviral vector by controlling the rate of viral
maturation or eliminating enzymatic degradation of genomic RNA in
the mature particles. Another interesting possibility would be to
create a MMuLV with enhanced natural endogenous reverse tran-
scription where viral RNA is retro-transcribed to DNA (Zhang et al.,
1995) soon after virus budding and maturation producing a more
stable DNA–RNA hybrid.
Materials and methods
Cell culture and virus harvesting
NIH 3T3 cells (ATCC CRL-1658), the amphotropic packaging cell
line Ψ-CRIP (kindly provided by L.K. Cohen of Somatix Therapy
Corporation, Alameda, California), which contains a MMuLV-derived
vector carrying the LacZ gene and produces the α-SGC-LacZ virus
(Danos and Mulligan, 1988; Price, Turner, and Cepko, 1987), and
COS-7 cells (ATCC CRL-1651) were cultured in Dulbecco's Modiﬁed
Eagle medium (DMEM; Gibco BRL, Gaithersburg, MD) with 10%
bovine calf serum (Hyclone Labs Inc., Logan, UT) containing 100 U/
mL penicillin and 100 μg/mL streptomycin (GIBCO BRL) (Dhawan et
al., 1991). Virus-containing medium was harvested from sub-
conﬂuent cultures of the virus-producing cell line, ﬁltered through
0.45 μm syringe ﬁlters (Millipore), stored at 4 °C or frozen on
pulverized dry ice and stored at −80 °C.
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Retrovirus was concentrated by adding PEG 8000 (Sigma-Aldrich)
to a ﬁnal concentration of 8% (w/v), followed by overnight incubation
at 4 °C and centrifugation at 1500 g for 45 min. The pellet was
resuspended in phosphate-buffered saline pH=7.4 (PBS) and dialyzed
overnight against PBS (cut off 300 kD) for Circular Dichroism analysis,
SDS-PAGE, and two-dimensional SDS-PAGE. The pellet was resus-
pended in fresh medium for the transduction assays. The integrity of
virus particles was veriﬁed by using a Zeta Plus light scattering
instrument (Brookhaven Instruments) and transduction assay.
Transduction efﬁciency assay
Transduction of the LacZ virus was measured by a microplate
assay (36). The day before transduction with the LacZ virus, a 10 cm
dish of conﬂuent 3T3 cells was treated with trypsin and the cells
obtained were counted with a Coulter counter model ZM (Coulter
Electronics, Hialeah, FL). Five thousand cells in 100 μL medium per
well were plated in a 96-well, ﬂat-bottom tissue culture dish with a
low-evaporation lid (Costar, Cambridge, MA) and growth at 37 °C,
10% CO2. The next day (16–24 h later), the medium was removed and
a LacZ-virus solution containing polybrene (Sigma-Aldrich) at a ﬁnal
concentration of 8 μg/mL was added to the cells. Two days after
transduction, the culture medium was removed and the cells were
washed with PBS. The cells were lysed with 50 μL of lysis buffer (PBS
with 1 mM MgCl2 and 0.5% Nonidet P-40) and incubated at 37 °C.
After 30 min, 50 μL of lysis buffer containing 6 mM ortho-nitrophenyl
β-D-galactopyranoside (ONPG, Sigma-Aldrich) warmed to 37 °C was
added to each well, and the plate was incubated at 37 °C for 45 min.
The reactions were stopped by the addition of 20 μL of stop buffer
(1 M Na2CO3). The plate was brought to room temperature and the
absorbance at 420 nm (A420) was measured in a plate reader
(Molecular Devices, Menlo Park, CA). Background corrections were
performed at 650 nm.
Production of virus mutants
Three plasmids (pVPack vectors: pVPackEco, pVPack-GP and
pFB-Neo-LacZ) carrying viral genes were purchased from Strata-
gene. The three pVPack plasmids were co-transfected in a COS-7 cell
line using a mammalian transfection kit (Stratagene) following the
manufacturer's instructions. In brief, COS-7 cells were seeded in 6-
well plates at 60–70% conﬂuence a day before transfection. Two
micrograms of each plasmid were co-transfected and after 12–24 h,
cells were washed twice with PBS and fresh medium was added.
Virus was harvested 12–24 h after the washing step and every 12 h
thereafter for the next 5 days. Virus production was followed using
RT-PCR. Samples were prepared by heating 100 μL of virus solution
at 95 °C for 15 min; 1 μl of sample was used as a template in the
reaction and was ampliﬁed using the One Step RT-PCR kit from
Qiagen. PCR without a reverse transcription step was performed to
detect possible residual or carry over plasmid DNA (derived from the
transfection procedure) in the virus samples. Protease and reverse
transcriptase mutants were created using the QuikChange mutagen-
esis kit (Stratagene) following the manufacturer's directions. Reverse
transcriptase mutants were designed based on the work of Blain and
Goff (1993). The primers used for the mutagenesis were the
following: R657S forward: gaccaagcggcctgcaaggcagccatcacag; R657S
reverse: ctgtgatggctgccttgcaggccgcttggtc; D524N forward: gacgcc-
gaccacacctggtacacgaatggaagcagtctcttac; D524N reverse: gtaaga-
gactgct tccat tgtgtaccaggtgtggtcggcgtc; Y586F forward:
gtttatactgatagccgttttgcttttgctactgcccatatccatgg; Y586F reverse:
ccatggatatgggcagtagcaaaagcaaaacggctatcagtataaac.
The protease defective (PR−) mutant was created based on the
work of Fu et al. (2006) using the following primers: D27N forward:cgtcaccttcctggtaaatactggggcccaacactccg; D27N reverse:
cggagtgttgggccccagtatctaccaggaaggtgacg. All mutations were within
the gag-pol gene present in the pVPack-GP plasmid, and mutations
were conﬁrmed by DNA sequencing analysis. Wild type virus was
produced using the non-mutated pVPack-GP plasmid and used as a
control in all the experiments in comparing the mutants. We
compared the bioactivity of the PR¯ retrovirus with wild type
produced under the same conditions, and we conﬁrmed that there
was no bioactivity for the PR¯ mutated virus.
Circular dichroism
CD analysis was performed on virus samples in PBS with an AVIV
202 CD spectrophotometer (AVIV Biomedical) using a cuvette with
path length of 0.1 cm. Samples were incubated at 37 °C for 13 h and
spectra were automatically collected every hour in the range 200 to
320 nm, with a step size of 0.2 nm.
Two-dimensional gel electrophoresis
Brieﬂy, 50 μg of total proteins from each sample was mixed with
125 μl of rehydration buffer containing 8 M urea, 2% CHAPS, 10 mM
DTT and 0.2% (pH 3–10) carrier ampholytes, and then loaded
overnight onto linear pH 3–6 or pH 5–8 IPG strips through passive
in-gel rehydration. After isoelectric focusing with a maximum of
5000 V for a total of 12,000 Vh at 20 °C and equilibrating ﬁrst in a
DTT buffer (15 min, 6 M urea, 2% (w/v) SDS, 0.5 M Tris/HCl, pH 6.8,
and 1% DTT), and then in an iodoacetamide buffer (15 min, 6 M urea,
2% SDS, 0.5 M Tris/HCl, pH 6.8, and 2.5% iodoacetamide), the IPG
strips were positioned on 10–15% (w/v) polyacrylamide gels for the
second-dimension separation at 200 V. The gel was stained with
SyproRuby ﬂuorescent dye according to the manufacturer's instruc-
tions (Molecular Probes, Eugene, OR, U.S.A.). The stained gel was
scanned with a Fluor-S MultiImager system (Bio-Rad) and analysed
with PDQuest software (version 7.0; Bio-Rad).
SDS-PAGE analysis
Brieﬂy, 50 μg of total protein from each sample was mixed with
sample buffer to a ﬁnal concentration of 1× according to standard
procedures and loaded on a 4–20% Precision precast polyacrylamide
gel (Pierce). After separation the gel was stained with Coomassie blue.
End point and real time RT-PCR
MMuLV-based α-SGC-LacZ-virus solution produced from stable
packaging cell line was incubated at 37 °C, and samples were collected
at different time points and frozen for later RNA puriﬁcation. Virus
was concentrated by PEG 8000 precipitation and RNA from each
sample was puriﬁed using QIAamp Viral RNA Minikit (Qiagen), and
quantiﬁed by absorption at 260 nm. For each sample a 5 ng/μL solution
was prepared and used for end point and real time RT-PCR using the
following primers: Gag forward: ccaggtaaactgacagctctgatcgagtctg;
Gag reverse: ggcccttgtgttattccttttaccttgg; LacZ forward:
ggtctgctgctgctgaacgg; LacZ reverse: atcgacagatttgatccagcgatacag. For
each set of primers a product of 200 base pairs is expected. End point
PCR was carried out on Mastercycler Epgradient-S (Eppendorf), using
the One Step RT-PCR kit (Qiagen). The reactions were prepared
following the manufacturer's instructions and using 5 ng total RNA as
a template for 30 cycles. Semi-quantitative analysis of the product was
performed using Quantity One software (Biorad).
The Natural Endogenous Reverse Transcription (NERT) was
investigated incubating the virus at 37 °C and 4 °C. Samples collected
at different time points were heated at 95 °C for 15 min and 2 μL of the
samples, without RNA extraction, were used as template in PCR
reaction without reverse transcription step. The ampliﬁcation
97M. Casali et al. / Virology 380 (2008) 91–98reactions were carried out for 40 cycles and semi-quantitative analysis
of the product was performed using Quantity One software.
Real time PCR was performed on a Light Cycler LC-24 (Idaho
Technology), using Omniscript and Sensiscript RT Kits (Qiagen) for
the reverse transcription reaction step and SuperScript III Platinum
CellsDirect Two-Step qRT-PCR Kits (Invitrogen) for quantitative PCR.
For reverse transcription, 5 ng of total RNA was used as template. For
real time ampliﬁcation, 1 μL of the reverse transcription reactions
was used as template. Because of the small volumes of viral mutants
and wild type control produced from transient transfection of COS-7
cell, samples for PCR analysis were prepared following a different
protocol: samples collected for decay experiments at 37 °C were
heated at 95 °C for 15 min. For end point RT-PCR and the reverse
transcription step, 2 μL of the sample without RNA extraction were
used. For real time PCR, 2 μL of the ten-fold diluted reverse
transcription reactions was used; for PCR analysis of mutants,
primers speciﬁc for the LacZ region were used. All reactions were
performed according to the manufacturer's instructions. A calibra-
tion curve was obtained using the pFB-Neo-LacZ plasmid as
template. Data obtained by real time PCR were ﬁtted using
exponential decay model.
Northern blot
Virus solutions previously harvested and frozen at −80 °C were
thawed and incubated at 37 °C over a period of 24 h. Samples, taken at
the beginning of the incubation (time zero) and after 24 h, were
subsequently stored at 4 °C. Virus particles were concentrated by
ultracentrifugation at 32,000 rpm for 1 h and 30 min and RNA was
extracted and quantiﬁed by UV absorbance. RNA samples were ﬁrst
denatured at 70 °C for 15 min in formaldehyde buffer (Formaldehyde
Sample Buffer, 5 X Cambrex) and then separated by 1.25% agarose gel
(Reliant Precast gels, Cambrex) in Mops buffer (Cambrex) at 70 V for
3 h. RNA was transfer by vacuum blotting on positively charged nylon
membrane (BrightStar®-Plus, Ambion) in 2× SSC buffer and cross-
linked at 80 °C for 2 h. Prehybridization was performed at 40 °C for
30 min in ULTRAhyb® Ultrasensitive Hybridization Buffer (Ambion).
The 50 base pair probe was radiolabeled with 32P (Rediprime II,
Amersham) following the manufacturer's instructions and denatured
at 90 °C for 10 min before being added to the membrane.
Hybridization was performed overnight at 40 °C. After hybridization,
blot was washed three times for 15 min at 55 °C with a solution
containing 2× SSC and 0.1% SDS. Damp blots were wrapped in plastic
wrap and exposed to PhosphoImager screen for 1 h and visualized on
a GE Typhoon Imager.
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